Return to Home PagePhysician Training Program
Return to Home PageThe INR® has successfully implemented a physician training program for those licensed physicians who are interested in learning how to perform and manage anti-TNF treatment of sciatica, back, and neck pain. Physician training is conducted at the INR in Los Angeles. Physician training usually requires at least a full day at the INR, with two days preferred for those physicians flying in from overseas, particularly for those physicians whose training will be conducted in languages other than English. Training includes review of relevant anatomy and physiology, detailed instruction in injection methods, dosing schedules, clinical response, clinical evaluation, and discussions with ongoing patients and their families. Trained physicians have been using the patented anti-TNF methods invented at the INR at their own clinics around the world.
For further information, please send an e-mail request to: nrimed@gmail.com
Tobinick E
The value of drug repositioning in the current pharmaceutical
market.
Drug News and Perspectives 2009 Jan-Feb 22(1).
Tobinick E
Perispinal etanercept for neuroinflammatory disorders.
Drug Discovery Today 2008 Dec 6. PubMed
19027875 link to abstract
Tobinick E
Perispinal etanercept produces rapid improvement in primary
progressive aphasia: Identification of a novel, rapidly reversible
TNF-mediated pathophysiologic mechanism.
Medscape J Med 2008; 10(6):135.
Tobinick EL, Gross H
Rapid improvement in verbal fluency and aphasia following perispinal
etanercept in Alzheimer's disease.
BMC Neurol 2008 Jul 21; 8(1):27.
Tobinick EL
Re: Inflammatory markers and the risk of Alzheimer disease:
the Framingham Study.
Neurology 2008 Apr 1; 70(14):1222-3; author reply 1223.
Tobinick EL
A critique of intradiscal administration for treatment of radiculopathy.
Anesthesiology 2008 Feb; 108(2):334; author reply 335.
Tobinick EL, Gross H
Rapid cognitive improvement in Alzheimer's disease following
perispinal etanercept administration.
J Neuroinflammation 2008 Jan 9; 5(1):2.
Tobinick E
Perispinal etanercept for treatment of Alzheimer's disease.
Curr Alzheimer Res 2007 Dec; 4(5):550-2.
Tobinick E
Spinal Delivery of p38: TNF-alpha Inhibitors.
PLoS Med 2006 Nov; 3(11):e511.
Tobinick E, Gross H, Weinberger
A, Cohen H.
TNF-alpha Modulation for Treatment of Alzheimer's Disease:
A 6-Month Pilot Study.
MedGenMed 2006; 8(2):25.
Tobinick E
The Cerebrospinal Venous System: Anatomy, Physiology, and Clinical
Implications.
MedGenMed 2006; 8(1):53.
Tobinick E, Davoodifar S
Efficacy of etanercept delivered by perispinal administration
for chronic back and/or neck disc-related pain: a study of clinical
observations in 143 patients.
Curr Med Res Opin 2004 Jul; 20(7):1075-85.
Tobinick E
TNF-alpha inhibition for potential therapeutic modulation of
SARS coronavirus infection.
Curr Med Res Opin 2004 Jan; 20(1):39-40.
Tobinick EL
Targeted etanercept for treatment-refractory pain due to bone
metastasis: two case reports.
Clin Ther 2003 Aug; 25(8):2279-88.
Tobinick EL
Targeted etanercept for discogenic neck pain: uncontrolled,
open-label results in two adults.
Clin Ther 2003 Apr; 25(4):1211-8.
Tobinick EL, Britschgi-Davoodifar
S
Perispinal TNF-alpha inhibition for discogenic pain.
Swiss Med Wkly 2003 Mar 22; 133(11-12):170-7.
